In the case of adenocarcinoma (even in dimorphic combination with squamous cell carcinoma), a molecular genetic assay of EGFR mutations (18–21 exons), BRAF, V600E, ALK, and ROS1 is recommended. This evidence concerns the gene BRAF and squamous cell carcinoma.